Search

Displaying results 6181 - 6190 of 9705 in total
  1. Drug

    Mericitabine

    go.drugbank.com/drugs/DB12045
    Investigational

    Mericitabine is a polymerase inhibitor being developed for the treatment of chronic hepatitis C. Mericitabine is a prodrug of PSI-6130, which demonstrated excellent potency in preclinical studies. … PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication.

  2. Drug

    Vesnarinone

    go.drugbank.com/drugs/DB12082
    Investigational

    Vesnarinone has been used in trials studying the treatment of HIV Infections and Sarcoma, Kaposi.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Tetrahydropalmatine

    go.drugbank.com/drugs/DB12093
    Investigational

    Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal

  4. Drug

    Gevokizumab

    go.drugbank.com/drugs/DB12119
    Investigational

    Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.

  5. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    tool kit to treat such a prevalent medical condition. … [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
  6. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    [A235725,A235735] Due to its formulation as a pro-drug brincidofovir also carries a greater bioavailability than cidofovir,[A235740,A235725] allowing for oral administration rather than intravenous. … It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity

  7. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides.

  8. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF).

  9. Drug

    Dupilumab

    go.drugbank.com/drugs/DB12159
    ApprovedInvestigational

    Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … [L7186] Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017.

    Products: DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300 mg/2ml, DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 200 mg/1.14ml
  10. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated [DB04844] [A32046]. … This allows less frequent dosing and a lower daily dose with improvement in tolerability [A32043].